Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...
REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitors REC-4539, a ...
Recursion entered into a definitive agreement to combine with Exscientia (EXAI) to add its technology-enabled clinical pipeline, sector-leading partnerships, and precision chemistry capabilities ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results